Abraxane meets goal in pivotal Phase III trial in lung cancer
This article was originally published in Scrip
Abraxis BioScience's chemotherapy Abraxane (protein-bound paclitaxel) has improved the primary response rate endpoint compared with standard Taxol (paclitaxel) when they were both combined with carboplatin in a registrational Phase III trial in first-line non-small cell lung cancer (NSCLC), leading to the company's shares to soar by 30% on Nasdaq on 17 March.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.